Literature DB >> 12615637

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

Christian Confavreux1, Sandra Vukusic, Patrice Adeleine.   

Abstract

Prognosis of multiple sclerosis is highly variable. Clinical variables have been identified that are assessable early in the disease and are predictors of the time from the disease onset to the onset of irreversible disability. Our objective was to determine if these clinical variables still have an effect after the first stages of disability have been reached. We determined the dates of disease onset and assignment of scores of irreversible disability in 1844 patients with multiple sclerosis. We used three scores on the Kurtzke Disability Status Scale as benchmarks of disability accumulation: 4 (limited walking but without aid); 6 (walking with unilateral aid); and 7 (wheelchair bound). We used Kaplan-Meier analyses and Cox regression models to determine the influence of the clinical variables on the time to disability onset. Median times from onset of multiple sclerosis to assignment of a score of 4, 6 and 7 were significantly influenced by gender, age, symptoms and course (relapsing-remitting or progressive) at onset of the disease, degree of recovery from the first relapse, time to a second neurological episode, and the number of relapses in the first 5 years of the disease. Similarly, times from onset of multiple sclerosis to a score of 6 and 7 were influenced by time to a score of 4. In contrast, none of the variables substantially affected the time from a score of 4 to a score of 6 or 7, or from a score of 6 to a score of 7. Early assessable clinical variables significantly influence the time from the onset of multiple sclerosis to the assignment of a disability score of 4, but not the subsequent progression of irreversible disability.

Entities:  

Mesh:

Year:  2003        PMID: 12615637     DOI: 10.1093/brain/awg081

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  189 in total

1.  A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy.

Authors:  Pietro Annovazzi; Valentina Tomassini; Benedetta Bodini; Laura Boffa; Massimiliano Calabrese; Eleonora Cocco; Cinzia Cordioli; Giovanna De Luca; Giovanni Frisullo; Antonio Gallo; Simona Malucchi; Damiano Paolicelli; Ilaria Pesci; Marta Radaelli; Paolo Ragonese; Luca Roccatagliata; Carla Tortorella; Marco Vercellino; Valentina Zipoli; Claudio Gasperini; Mariaemma Rodegher; Claudio Solaro
Journal:  Neurol Sci       Date:  2012-03-11       Impact factor: 3.307

2.  Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).

Authors:  O Fernández; V Fernández; T Arbizu; G Izquierdo; I Bosca; R Arroyo; J A García Merino; E de Ramón
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

3.  17beta-estradiol protects male mice from cuprizone-induced demyelination and oligodendrocyte loss.

Authors:  Lorelei C Taylor; Kasturi Puranam; Wendy Gilmore; Jenny P-Y Ting; Glenn K Matsushima
Journal:  Neurobiol Dis       Date:  2010-03-27       Impact factor: 5.996

Review 4.  Benign multiple sclerosis: does it exist?

Authors:  Jorge Correale; María C Ysrraelit; Marcela P Fiol
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

5.  Cortical excitability changes over time in progressive multiple sclerosis.

Authors:  Samar S Ayache; Alain Créange; Wassim H Farhat; Hela G Zouari; Catherine Lesage; Ulrich Palm; Mohammed Abdellaoui; Jean-Pascal Lefaucheur
Journal:  Funct Neurol       Date:  2015 Oct-Dec

6.  Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Authors:  Valentina Tomassini; Andrea Paolillo; Pierluigi Russo; Elisabetta Giugni; Luca Prosperini; Claudio Gasperini; Guido Antonelli; Stefano Bastianello; Carlo Pozzilli
Journal:  J Neurol       Date:  2005-09-14       Impact factor: 4.849

Review 7.  Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.

Authors:  Regina Berkovich; Mark A Agius
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

8.  Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France.

Authors:  M Debouverie; S Louis; S Pittion-Vouyovitch; T Roederer; H Vespignani
Journal:  J Neurol       Date:  2007-06-25       Impact factor: 4.849

9.  XY sex chromosome complement, compared with XX, in the CNS confers greater neurodegeneration during experimental autoimmune encephalomyelitis.

Authors:  Sienmi Du; Noriko Itoh; Sahar Askarinam; Haley Hill; Arthur P Arnold; Rhonda R Voskuhl
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

10.  Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

Authors:  Ray Gani; Gavin Giovannoni; David Bates; Belinda Kemball; Steve Hughes; John Kerrigan
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.